Close Menu

NEW YORK (GenomeWeb) – Invitae announced after the close of the market on Monday that it will offer $125 million worth of its common stock in a public offering.

The San Francisco-based genetic testing firm hasn't finalized the number of shares it will offer of the expected offering price. Its shares were trading down around 5 percent at $19.35 on the New York Stock Exchange on Tuesday morning.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.